Clin Case Rep Int | Volume 6, Issue 1 | Research Article | Open Access
Chen CP1, Ong KH1, Chen MJ1, Tian YF1 and Sun DP1,2*
1Department of Surgery, Division of General Surgery, Chi-Mei Medical Center, Tainan, Taiwan
2Department of Surgery, Division of Transplant Surgery, Chi-Mei Medical Center, Tainan, Taiwan
*Correspondance to: Ding-Ping SunFulltext PDF
Liver transplant is a lifesaving therapy for patients with end-stage liver disease who exhibit massive ascites, hepatic encephalopathy, and a high risk of esophageal bleeding due to liver decompensation. The shortages in liver donations leave these patients waiting in despair. Prior to the approval of direct-acting antiviral agents (DAAs), Hepatitis C Virus (HCV)–positive liver grafts were discarded three times more than HCV-negative grafts. However, with the use of DAAs, transplants from HCV-positive donors into HCV-negative recipients have become feasible and safe. The high serum virologic response rate obtained with DAA therapy is a milestone in the treatment of HCV infection. Few studies have focused on living HCV-positive donor liver transplants to HCV-negative recipients. We present an HCV-positive donor who received 8-week DAA therapy before donating the liver to her seriously ill HCV-negative relative. The donor’s recovery was uneventful, and the recipient was stable during the perioperative period and postoperative follow-up.
Living donor liver transplant; Hepatitis C-seropositive donor; Seronegative recipients
Chen CP, Ong KH, Chen MJ, Tian YF, Sun DP. Living Donor Liver Transplant from a Hepatitis C–Seropositive Donor into a Seronegative Recipient: A Case Report. Clin Case Rep Int. 2022; 6: 1439.